PHE's Goldman in Fortune: Innovative Drugs Deserve Innovative Pricing
PHE cofounder Dana Goldman, along with coauthor David Agus, contribute a new commentary for Fortune.com. Discussing the significance of Kymriah, the first gene therapy for cancer to achieve FDA approval, Goldman and Agus make the point that although the promise and pricing of the new drug is grabbing all the headlines, the accompanying risk sharing agreement between CMS and Novartis is even more significant.
To read the complete article, please click here.
In this unique one-hour webinar, Dr. Jena outlines a broader framework for assessing value to improve identification of not only the highest-value treatments, but also low-value therapies on which spending can safely be reduced.